Citations

Clear

3057 citation(s) found for "Cd, Johnson".

AI-Augmented Kidney Stone Composition Analysis with Auto-Release Improves Quality, Efficiency, Cost–Effectiveness, and Staff Satisfaction
Day, Patrick L. , Rokke, Denise, Schneider, Laura, Abbott, Jillian, Holmen, Brenda, Wieczorek, Mikolaj A. , Carter, Rickey E. , Bornhorst, Joshua A. , Jannetto, Paul J. , Johnson, Patrick, Carter, Rickey E , Bornhorst, Joshua , Day, Patrick , Schneider, Laura, Holmen, Brenda, Johnson, Patrick W. , Kunze, Katie L.

Mayo Clinic

The Journal of Applied Laboratory Medicine | December 19, 2024 | Volume: 10 | Issue: 2 | Pages: 305-314

10.1093/jalm/jfae146 | PMID 39700400 Get It

Abstract Background We sought to evaluate key performance indicators related to an internally developed and deployed artificial intelligence (AI)-augmented kidney stone composition test system for potential improvements in test quality, efficiency, cost-effectiveness, and staff satisfaction. Methods We compared quality, efficiency, staff satisfaction, and financial data from the 6 months after the AI-augmented laboratory test system was deployed (test period) with data from the same 6-month period in the previous year (control period) to determine if AI-augmentation improved key performance indicators of this laboratory test. Results In the 6 months following the deployment (test period) of the AI-augmented kidney stone composition test system, 44 830 kidney stones were analyzed. Of these, 92% of kidney stones were eligible for AI-assisted interpretation. Out of these AI-eligible stones, 45% were able to be auto-released by the AI-augmented test system without human secondary review. Furthermore, the new AI-augmented kidney stone test system resulted in an apparent 40% reduction in incorrect laboratory results. Additionally, the new AI-augmented test system improved laboratory efficiency by 20%, improved staff satisfaction, and reduced the average analysis cost per kidney stone by $0.23. Conclusions The AI-augmented test system improved test quality, efficiency, cost-effectiveness and staff satisfaction related to this kidney stone composition test.
A Prospective, Randomized, Noninferiority Study to Evaluate the Safety and Effectiveness of Steerable Ureteroscopic Renal Evacuation Compared with Standard Ureteroscopy: 30-Day Results of the ASPIRE Study
Matlaga, Brian R., Johnson, Brett A. , Page, Jay, Wolf, J. Stuart, Preminger, Glenn M. , Jones, Loren, Sobol, Ilya , Stern, Karen , Cuellar, David, Cobb, Kaitlan, Barsky, Robert I, Medairos, Robert, Marguet, Charles G., Nimmagadda, Naren , Chi, Thomas , Johnson, Brett , Stern, Karen L , Mueller, Thomas J. , Jones, Loren, White, Mark, Levin, Michael

Mayo Clinic

Journal of Endourology | December 19, 2024 | Volume: 39 | Issue: 1 | Pages: 10-18

10.1089/end.2024.0602 | PMID 39699687 Get It

Purpose: We report the first multicenter, prospective, randomized noninferiority controlled trial of steerable ureteroscopic renal evacuation (SURE) for nephrolithiasis treatment. Materials and Methods: Candidates for laser lithotripsy ≥18 years with ≥1 renal stone ≥7 mm and 7–20 mm stone burden were randomized 1:1 SURE vs ureteroscopy (URS). SURE was performed using the CVAC Aspiration System, a novel steerable irrigation–aspiration catheter. The primary efficacy end point was noninferiority in stone-free rate (SFR) based on zero residual fragments (RFs) 30 days postprocedure on noncontrast computed tomography. Secondary end points were superiority tests, stone clearance (percent stone volume reduction), residual stone volume (RSV), SFR (no RF >2 mm), and SFR (no RF >4 mm) 30 days postprocedure. Results: Of the subjects, 123 were randomized and 101 qualified for efficacy analysis (SURE 46 vs URS 55). Despite randomization, baseline URS stone volume was higher (SURE 485.0 ± 432.5 mm 3 vs URS 713.3 ± 558.5 mm 3 ). The primary noninferiority end point was achieved (SURE SFR 48% vs URS SFR 49%, p = 0.027, −1.3% [90% confidence interval; −18%, 15%]). Stone clearance was significantly higher for SURE vs URS subjects (SURE 96.9 ± 5.6% vs URS 92.9 ± 11.6%, p = 0.036); RSV was significantly lower (SURE 14.3 ± 3 0.9 mm 3 vs URS 70.2 ± 144.9 mm 3 , p = 0.012). SURE stone clearance and RSV were independent of baseline stone volume, but for URS degraded with increasing baseline stone volume. Safety was comparable between groups. Conclusions: SFR for SURE subjects was noninferior compared with URS subjects; stone clearance and RSV were significantly better with SURE, independent of baseline stone volume.
Molecular profile of adult primary leptomeningeal gliomatosis aligns with glioblastoma, IDH ‐wildtype
Carabenciov, Darin D., Trejo‐Lopez, Jorge , Nguyen, Aivi T. , Ida, Cristiane M. , Zepeda‐Mendoza, Cinthya , Dasari, Surendra , Russler-Germain, Emilie V. , Quezado, Martha , Aldape, Kenneth , Giannini, Caterina, Zhu, Yi , Trejo-Lopez, Jorge A, Ida, Cristiane M , Russler-Germain, Emilie , Dahiya, Sonika , Nguyen, Aivi T , Johnson, Derek R. , Raghunathan, Aditya , Lanzino, Giuseppe , Dahiya, Sonika

Mayo Clinic

Brain Pathology | December 18, 2024 | Volume: 35 | Issue: 4 | Pages: No page available

10.1111/bpa.13326 | PMID 39692003 Get It

Abstract Adult primary leptomeningeal gliomatosis (PLG) is a rare, rapidly progressive and fatal disease characterized by prominent leptomeningeal infiltration by a glial tumor without an identifiable parenchymal mass. The molecular profile of adult PLG has not been well‐characterized. We report the clinical, pathological, and molecular findings of six adult PLG patients (five males and one female), median age 58 years. All cases exhibited pathological leptomeningeal enhancement at presentation. Leptomeningeal biopsy was diagnostic in five (of six) cases, revealing infiltration by an astrocytic glioma with mitotic activity, lacking microvascular proliferation or necrosis. One case was diagnosed at autopsy. All tumors were IDH‐wildtype, with five harboring TERT promoter mutations. Additional mutations identified were PTEN in one case, TP53 in two cases, and NF1 in two cases. A chromosome profile with +7/−10 was found in four cases, whereas the remaining two showed either chromosome 7 or 7p gain only. Four cases showed chromosome 9p loss with CDKN2A/B homozygous deletion, one case showed hemizygous CDKN2A/B loss, and one case showed intact chromosome 9 and CDK4/GLI1 amplification. DNA methylation profiling was performed in four cases and revealed a match to glioblastoma (GBM) family and mesenchymal typical class with high confidence scores in two cases; the other two cases showed only suggestive combined scores for GBM family and mesenchymal atypical class. The molecular profile of all cases closely aligned with that of adult‐type GBM, IDH‐wildtype, CNS WHO grade 4. All patients succumbed to the disease. In five cases with extensive leptomeningeal disease at diagnosis, the course was rapid, with median survival of 24 days following palliative care. Only one case, with relatively localized disease at diagnosis, received chemoradiation therapy and survived 535 days, raising the possibility that early diagnosis and timely treatment could improve outcome. A detailed list of previously reported cases is provided in a supplementary table.
Supporting Patient Involvement in U.S. Medical Education Through Changes in Accreditation
Tackett, Sean , Steinert, Yvonne , Adams, Gayle Johnson, Reed, Darcy A. , Whitehead, Cynthia , Wright, Scott M. , Whitehead, Cynthia R , Wright, Scott M , Jackson, Jeffrey L.

Mayo Clinic

Teaching and Learning in Medicine | December 15, 2024 | Volume: 38 | Issue: 1 | Pages: 116-125

10.1080/10401334.2024.2439850 | PMID 39676226 Get It

Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent
Gangat, Naseema , Elbeih, Azeem, Ghosoun, Nour, McCullough, Kristen , Aperna, Fnu, Johnson, Isla McKerrow , Abdelmagid, Maymona, Al‐Kali, Aref , Begna, Kebede H. , Elliott, Michelle A. , Mangaonkar, Abhishek A. , Matin, Aasiya , Litzow, Mark R. , Patnaik, Mrinal M. , Pardanani, Animesh , Badar, Talha , Foran, James M. , Palmer, Jeanne , Sproat, Lisa, Khera, Nandita , Yi, Cecilia Y. Arana , Yates, Samuel J. , Sneider, Abigail , Dworkin, Emily , Patel, Anand , Bazinet, Alexandre , Kadia, Tapan M. , Tefferi, Ayalew , Johnson, Isla M, Begna, Kebede , Elliott, Michelle , Mangaonkar, Abhishek A. , Saliba, Antoine N , Hefazi, Mehrdad , Litzow, Mark R. , Shah, Mithun V , Patnaik, Mrinal , Pardanani, Animesh , Badar, Talha , Murthy, Hemant S , Arana Yi, Cecilia Y , Patel, Anand , Bazinet, Alexandre , Senapati, Jayastu , Bataller, Alex , DiNardo, Courtney , Kadia, Tapan M , Tefferi, Ayalew , McCullough, Kristen B , Alkhateeb, Hassan B. , Saliba, Antoine N. , Hefazi, Mehrdad , Hogan, William J. , Shah, Meera , Murthy, Hemant S. , Yi, Cecilia Arana , Senapati, Jayastu , DiNardo, Courtney D.

Mayo Clinic

American Journal of Hematology | December 13, 2024 | Volume: 100 | Issue: 2 | Pages: 260-271

10.1002/ajh.27564 | PMID 39671248 Get It

ABSTRACT Patients with newly diagnosed acute myeloid leukemia (ND‐AML) derive variable survival benefit from venetoclax + hypomethylating agent (Ven‐HMA) therapy. The primary objective in the current study was to develop genetic risk models that are predictive of survival and are applicable at the time of diagnosis and after establishing treatment response. Among 400 ND‐AML patients treated with Ven‐HMA at the Mayo Clinic, 247 (62%) achieved complete remission with (CR) or without (CRi) count recovery. Multivariable analysis–derived hazard ratios (HR), including 1.8 for European LeukemiaNet (ELN) adverse karyotype, 4.7 for KMT2Ar , 1.7 for TP53 MUT , 2.6 for KRAS MUT , and 2.1 for IDH2 WT were applied to develop an HR‐weighted risk model: low, intermediate, and high; respective median survival censored for allogeneic stem cell transplant (ASCT) (3‐year survival) were “not reached” (67%), 19.1 (33%), and 7.1 months (0%). In patients achieving CR/CRi, adverse karyotype, KMT2Ar , KRAS MUT , IDH2 WT predicted inferior survival, allowing for a complementary response‐stratified risk model. The model was externally validated and was shown to be superior to the ELN 2024 risk model (AIC 179 vs. 195 and AUC 0.77 vs. 0.69). Survival was inferior with failure to achieve CR/CRi or not receiving ASCT; 3‐year survival for high‐risk with or without ASCT was 42% versus 0% ( p < 0.01); intermediate 72% versus 43% ( p = 0.06); and low‐risk 88% versus 78% ( p = 0.53). The Mayo genetic risk models offer pre‐treatment and response‐based prognostic tools for ND‐AML treated with Ven‐HMA. The current study underscores the prognostically indispensable role of achieving CR/CRi and ASCT.
Aerodigestoscopy (ADS): The Feasibility, Safety, and Comfort of a Comprehensive Procedure for the Evaluation of Physiological Disorders of the Aerodigestive Tract
Arnold, Robert , Bausek, Nina , Gaskill, Christopher S. , Johnson, Lawrence F., Aldarondo, Sigfredo, Aull, Cody, Midani, Malik , Midani, Tarek , Midani, Ramiz, Brown, Ashton S., Wallace, Alana, Arnold, Robert J , Gaskill, Christopher S , Bausek, Nina

Mayo Clinic

Journal of Clinical Medicine | December 13, 2024 | Volume: 13 | Issue: 24 | Pages: 7578

10.3390/jcm13247578 | PMID 39768501 Get It

Background: Limited access to the comprehensive assessment of disorders of the upper aerodigestive tract is a barrier to care in rural health facilities. Assessment of the full aerodigestive tract requires a variety of specialists. The inability to access the necessary specialists can result in misdiagnosis, underdiagnosis, and increased associated mortality. Currently, no single differential diagnostic exam comprehensively assesses all functions of the upper aerodigestive tract to bridge this gap. The purpose of this study is to investigate the feasibility and safety of a novel procedure called ADS that can bridge this gap. Methods: Results from 18,464 ADS procedures were retrospectively analyzed for feasibility, safety and comfort. Results: 96.8% of ADS procedures were successfully completed without complication, confirming the efficacy of the procedure. Conclusions: ADS is a single procedure for the assessment of physiological functions of the upper aerodigestive tract, including swallow, voice, respiration, and cough while also screening for impaired gastric retention and obstructive sleep apnea, which may pose additional urgent and emergent airway threats. ADS may improve health outcomes in underserved populations, e.g., those in a rural community, referred to by other health professionals due to complaints of aerodigestive symptoms and signs.
Research setting in regional anaesthesia: a call for action
Chuan, Alwin , Johnson, Rebecca L. , McCartney, Colin J. L. , Chuan, Alwin , Johnson, Rebecca L

Mayo Clinic

Anaesthesia | December 11, 2024 | Volume: 80 | Issue: 4 | Pages: 357-361

10.1111/anae.16518 | PMID 39658860 Get It

Member Adherence to a Health Insurer-Sponsored Gap Closure Program Using Multi-Target Stool DNA Test for Colorectal Cancer Screening
Greene, Mallik , Pew, Timo, Le, Quang A. , Philp, Alisdair R. , Johnson, William K. , Doré, Michaël , Kisiel, John, Ebner, Derek, Johnson, William K., Ozbay, A. Burak , Kisiel, John B. , Ebner, Derek W. , Fendrick, A. Mark , Limburg, Paul J.

Mayo Clinic

Journal of Primary Care & Community Health | December 10, 2024 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/21501319241305958 | PMID 39655481 Get It

Objectives: To describe member adherence to a mail-based, health insurer-sponsored gap closure program for colorectal cancer (CRC) screening using multi-target stool DNA (mt-sDNA; Cologuard ® ) tests. Methods: Combined patient data from Exact Sciences Laboratories LLC and data from mass-mailed mt-sDNA orders placed by a large Medicare Advantage Insurance Plan were analyzed (03/01/2023-06/30/2023). Adherence and time to test return were the primary and secondary outcomes, respectively. Their association with patient characteristics was evaluated using multivariable regression. Results: Among the 3201 member-patients included (86.6% aged 65-75 years; 58.7% female), adherence rate was 49.4%, and mean time to test return was 25.5 days. After multivariable adjustment, the odds of test return were significantly higher among 65- to 75-year-olds (odds ratio [OR] = 1.59 relative to 45- to 64-year-olds), those living in small towns (OR = 1.43 relative to metropolitan-located individuals), and with digital outreach via both SMS and email (OR = 4.31 relative to no digital outreach). Time to test return was shorter in 65- to 75-year-olds than in 45- to 64-year-olds and was not associated with other patient characteristics. Conclusions: Mass-mailed mt-sDNA tests for CRC screening were associated with an overall adherence rate of about 50% in this Medicare Advantage population, with higher likelihood of test return among patients receiving digital outreach.
Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors (Children's Oncology Group ADVL1823)
Laetsch, Theodore W. , Voss, Stephan D. , Ludwig, Kathleen , Hall, David , Barkauskas, Donald A. , DuBois, Steven G. , Ronan, Joan, Rudzinski, Erin R. , Memken, Amanda , Robinson, Krystal, Sorger, Joel, Bhatla, Teena, Church, Alanna J. , Fox, Elizabeth , Weigel, Brenda J. , Voss, Stephan D , Reid, Joel M , Crompton, Brian D , Church, Alanna J , Fox, Elizabeth , Weigel, Brenda J , Teachey, David T , Reid, Joel M. , Crompton, Brian D.

Mayo Clinic

Journal of Clinical Oncology | December 9, 2024 | Volume: 43 | Issue: 10 | Pages: 1188-1197

10.1200/jco-24-01854 | PMID 39652801 Get It

PURPOSE The TRK inhibitor larotrectinib is US Food and Drug Administration approved for NTRK fusion–positive solid tumors that lack a satisfactory alternative or have progressed after treatment but has not been systematically studied as a frontline therapy with a defined duration of treatment. ADVL1823 evaluated larotrectinib in patients with newly diagnosed NTRK fusion–positive solid tumors with response-adapted duration of therapy and local control. METHODS Patients received larotrectinib twice daily in 28-day cycles for a predefined duration of treatment, ranging from 6 to 26 cycles depending on response to therapy and surgical resectability. The primary end point was the objective response rate (ORR) within six cycles in patients with infantile fibrosarcoma (IFS); patients with other histologic diagnoses were analyzed in a separate cohort. Secondary objectives included event-free survival (EFS) and overall survival (OS). RESULTS Thirty-three patients were enrolled: 18 with IFS and 15 with other solid tumors. The ORR within six cycles was 94% (17/18; 95% adjusted CI, 72.7 to 98.6) among children with IFS and 60% (9/15; 95% CI, 32.3 to 83.7) among children with other solid tumors. Six percent (2/33; 95% CI, 0.7 to 22.2) patients developed progressive disease while on therapy. Two-year EFS and OS among these groups were 82.2% (95% CI, 54.3 to 93.9) and 93.8% (95% CI, 63.2 to 99.1) for IFS and 80% (95% CI, 50.0 to 93.1) and 93.3% (95% CI, 61.3 to 99.0) for other solid tumors, respectively. Patients undergoing surgical resection of their tumor had prolonged EFS, with only 1 of 16 such patients experiencing disease progression. Four of 33 patients had dose-limiting toxicities. CONCLUSION Larotrectinib is highly active in patients with newly diagnosed NTRK fusion–positive solid tumors. Larotrectinib should be a frontline option for patients with IFS and other NTRK fusion–positive solid tumors. Local control with surgical resection remains important in the treatment of patients with IFS.